v3.26.3
Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Aug. 24, 2026
Aug. 21, 2026
Aug. 20, 2026
Jul. 31, 2026
Jun. 29, 2026
Jun. 26, 2026
Jun. 05, 2026
Jun. 02, 2026
May 20, 2026
Apr. 30, 2026
Apr. 02, 2026
Oct. 24, 2025
Sep. 30, 2025
Sep. 05, 2025
Jul. 02, 2025
Jun. 03, 2024
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Jul. 22, 2026
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Common stock, shares authorized 500,000,000                                 500,000,000   500,000,000   500,000,000  
Preferred stock, shares authorized 5,000,000                                 5,000,000   5,000,000   5,000,000  
Common stock, shares issued 1,318,521                                 1,318,521   1,318,521   459,286  
Common stock, shares outstanding 1,318,521                                 1,318,521   1,318,521   459,286  
Preferred stock, shares issued                                      
Preferred stock, shares outstanding                                      
Forgivness of accrued compensation                                       $ 875,315      
Equity consideration amount                                   $ 889,478   889,478      
Cash obligation                                       $ 1,058,546    
Sale of shares of common stock             213,333                     13,466       267  
Sale of Stock, Price Per Share $ 17.51                                 $ 17.51   $ 17.51      
Aggregate proceeds share issuance                                   $ 87,055       $ 22,251  
Proceeds before offering expenses                                       $ 3,719,998    
Share based compensation arrangement description               the Company entered into Amendment No. 3 to Alison Silva’s employment agreement, appointing Ms. Silva as Chief Operating Officer and President and increasing her base salary to $340,200 from $315,000. In connection with the amendment, on June 2, 2026, the Board approved a one-time option grant to Ms. Silva to purchase up to 8,000 shares of common stock under the 2025 Equity Incentive Plan, vesting over three years commencing September 2, 2026 in equal quarterly installments.                              
Stock options issued 192,765               2,666                 192,765   192,765      
Vested performance description           On June 29, 2026, in connection with his appointment to the Board of Directors, the Company granted Tomas J. Philipson, Ph.D. options to purchase an aggregate of 7,152 shares of common stock under the 2025 Equity Incentive Plan. The grants consisted of (i) an option to purchase 1,200 shares in connection with his appointment and (ii) an option to purchase 5,952 shares in lieu of the annual cash retainer and committee fees otherwise payable for his service on the Board and its committees.                                  
Stock-based compensation expense related to shares issued for services                                       $ 46,750 66,000    
Issued of aggregate fair value shares                     1,333                        
Number of restricted shares issued, value                                            
Compensation expense for services                                   $ 389,707 $ 389,707        
Share price $ 62.33                                 $ 62.33   $ 62.33   $ 77.56  
Vested, term                                       6 years 7 months 6 days   5 years 4 months 24 days  
Stock options issued 192,765                                 192,765   192,765   156,331  
Stock-based compensation expense                                       $ 1,543,863      
Stock-based compensation expense related to equity awards                                   $ 551,874 792,725 $ 1,497,113 $ 1,676,667    
Percentage of restricted stock units vested on grant date                     25.00%                        
Restricted shares outstanding 1,333                                 1,333   1,333      
Vested shares                                       583      
Unvested shares 750                                 750   750      
Unrecognized stock-based compensation $ 1,592,908                                 $ 1,592,908   $ 1,592,908      
Recognized over a period                                       2 years 3 months 18 days      
Two Consultants [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Stock granted                       2,666     4,996                
Share price                       $ 27.75     $ 92.25                
Fair value of grant date                       $ 73,982     $ 340,900                
Vested, term                       10 years                      
Stock options vest percentage                       25.00%     25.00%                
Option vested                       2,000     3,747                
Office Employees [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Stock granted                 46,684                            
Share price                 $ 20.85                            
Fair value of grant date                 $ 973,487                            
Vested, term                 10 years                            
Stock options vest percentage                 25.00%                            
Director [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Stock granted           7,152                                  
Share price           $ 21.00                                  
Fair value of grant date           $ 150,192                                  
Vested, term           10 years                                  
Andrew J. Cutler [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Stock granted         6,296                                    
Share price         $ 6.75                                    
Board of Directors [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Share price                               $ 89.25              
Stock options issued                               4,765              
Vesting period description                               The stock options have a 10-year term and vest in equal installments over a three (3) year period beginning on the grant date of July 2, 2025, subject to the officers’ continued employment at the time of vesting.              
One Consultants [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Stock granted                           1,465                  
Share price                             $ 92.25                
Fair value of grant date $ 100,000                                            
Consultants [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Vested performance description (a) 15% per Ambassador (maximum of three) referred by consultant and subsequently engaged by the Company, (b) 20% if consultant is instrumental in arranging a distribution arrangement not previously pursued by the Company, on terms acceptable to the Company, (c) 20% when such Distribution Contract achieves $1 million in annual sales and (d) 15% when the consultant arranges the first Celebrity Golf Tournament featuring Nugevia on terms and conditions acceptable to the Company.                                            
2025 Equity Incentive Plan [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Stock options issued                 28,820                            
Convertible Note One [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Sale of shares of common stock                                       290,874      
Net proceeds                                       $ 5,218,365      
2025 Convertible Notes [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Shares of common stock upon conversion of convertible notes                                       1,519      
Common Stock [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Equity consideration amount                                   13   $ 13      
Stock options issued                 1,333                            
Shares issued for services                                       667 1,376    
Stock-based compensation expense related to shares issued for services                                          
Issued of aggregate fair value shares                                       21,680      
Number of restricted shares issued, value                                       $ 2      
Stock-based compensation expense related to equity awards                                        
Common Stock [Member] | IPO [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Number of stock purchase                                 500            
Aggregate proceeds share issuance                                 $ 150,000            
Issued of aggregate fair value shares                                 46,500            
Number of restricted shares issued, value                                 $ 4,638,375            
Share purchase price                                 $ 99.75            
Common Stock [Member] | IPO [Member] | Entity Three [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Issued of aggregate fair value shares                                 15,500            
Pharm Ala License Agreement [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Number of stock purchase       132,867                                      
Equity consideration amount       $ 889,478                                      
Remaining share issuance       181,529                                      
Cash obligation       $ 1,058,546                                      
Securities Purchase Agreement [Member] | Common Stock [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Sale of shares of common stock     307,692             95,238                          
Sale of Stock, Price Per Share     $ 6.50             $ 21.00                          
Aggregate proceeds share issuance   $ 2,000,000.0               $ 2,000,000.0                          
Placement agent fees     $ 140,000             140,000                          
Proceeds before offering expenses     $ 1,860,000             $ 1,860,000                          
Standby Equity Purchase Agreement [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Net proceeds                                           $ 5,100,000  
Standby Equity Purchase Agreement [Member] | Convertible Note One [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Sale of shares of common stock                                       292,393      
Net proceeds                                       $ 5,218,006      
Standby Equity Purchase Agreement [Member] | 2025 Convertible Notes [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Shares of common stock upon conversion of convertible notes                                       1,519      
Standby Equity Purchase Agreement [Member] | Maximum [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Aggregate proceeds share issuance                         $ 20,000,000.0                    
2025 Equity Incentive Plan [Member]                                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                                              
Number of shares available for issuance                                             70,000